The first patient in The 2clinical admission group of THE CHINESE Phase 2 clinical lying drug ROS1/NTRK inhibitors.

On July 21st, the innovative drug research and development company YanYuan Pharmaceuticals announced that its next-generation ROS1/NTRK inhibitor talettctinib (AB-106) was the first in AU for a Phase 2 clinical trial of advanced non-small cell lung cancer (NSCLC) of the ROS1 fusion gene or systemic metastasis.
this one-arm, open clinical study evaluating the effectiveness and safety of patients with advanced non-small cell lung cancer with AB-106 treatment or systemic metastasis, with Professor Zhou Caixuan of Shanghai Lung Hospital as the national leading researcher.
Talectctinib is a new, effective, highly selective next-generation ROS1 and NTRK dual-target small molecule inhibitor that crosses the blood-brain barrier.
the research project was originally developed by Daiichi Sankyo, and in December 2018, The Pharmaceuticals acquired the drug's exclusive global rights in development, production and commercialization.
note, just last week, Yu Yuan Pharma announced a partnership with NewG Lab Pharma of Korea to award its exclusive interest in clinical development and commercialization in the Korean market.
, Taletrectinib has completed Phase 1 clinical trials in Japan and the United States to treat patients with ROS1 or NTRK fusion gene solid tumors, and Phase 2 clinical trials (NCT04395677) are under way.
last month, a phase 1 clinical data from taletrectinib was published online by Clinical Cancer Research, a oncology journal of the American Association for Cancer Research (AACR).
the study was conducted in patients with solid tumors in the United States, and the results showed that taletctinib had controlled toxicity at 800 mg of MTD per day, and had observed initial efficacy in patients with ROS1 plus non-small cell lung cancer who were resistant to creade.
in China, the drug was approved in China in March this year for two clinical studies of NSCLC with the ROS1 fusion gene and non-tumor patients carrying the NTRK fusion gene. founded in November 2018,
Yuyuan Pharmaceuticals is a clinical biopharmaceutical company that develops new tumor therapies.
early 2019, the company completed a round of financing of about RMB100 million, with an exclusive investment by Decheng Capital.
congratulates the clinical development of the drug ROS1/NTRK inhibitor taletctinib on new progress and hopes that the drug will go well in clinical lying next and bring new treatment options to patients as soon as possible.
original title: Treatment of non-small cell lung cancer! The first patient in The 2clinical admission group of THE CHINESE Phase 2 clinical lying drug ROS1/NTRK inhibitors.